On February 3, 2011 Canadian biopharmaceutical company Theratechnologies (TSX:TH), announced that it had entered into a distribution and licensing agreement with Ferrer Internacional S.A. ("Ferrer"), for the commercialization rights to tesamorelin in Europe, Russia, South Korea, Taiwan and certain central Asian countries for the treatment of excess abdominal fat in HIV-infected patients with lipodystrophy.
Ferrer will be responsible for conducting all regulatory and commercialization activities in connection with tesamorelin for the treatment of excess abdominal fat in HIV-infected patients with lipodystrophy in the territories subject to the agreement. Theratechnologies will be responsible for the manufacture and supply of tesamorelin to Ferrer. Theratechnologies has the option to co-promote tesamorelin for the reduction of excess abdominal fat in HIV-infected patients with lipodystrophy in the territories. Theratechnologies has kept all development rights to tesamorelin for other indications and will be responsible for conducting research and development for any additional programs. Ferrer has the option to enter into a co-development and commercialization agreement using tesamorelin relating to any such new indications.
Theratechnologies was advised in the negotiation of this agreement from the London office of Fasken Martineau by Stuart Richards with Antonina Cuffaro, Gary Howes and Paul Ranson.